HHS Secretary Kennedy announces that 14 previously restricted peptides will return to Category 1, restoring access through compounding pharmacies with a prescription.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list would be moved back to Category 1. This reclassification restores legal access to these compounds through licensed compounding pharmacies when prescribed by a physician.
The peptides returning to Category 1 include several of the most widely used compounds in the research and therapeutic community: BPC-157, Thymosin beta-4 fragment (TB-500), CJC-1295, Ipamorelin, Semax, GHK-Cu, MOTS-C, KPV, Epitalon, DSIP, GHRP-2, GHRP-6, Kisspeptin-10, Melanotan II, and PEG-MGF. Five peptides remain on the Category 2 restricted list.
It is important to note that reclassification to Category 1 does not equal FDA approval. These peptides have not undergone the formal clinical trial process required for New Drug Application approval. However, the change does mean that compounding pharmacies can once again legally prepare and dispense these compounds, giving patients and providers a regulated pathway to access them rather than relying on unregulated gray-market sources.
Source: Peptibase
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.